Search results for "Resection"

showing 10 items of 385 documents

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic c…

2019

480 Background: Hepatic metastasectomy is the only potential curative treatment option for stage IV colorectal cancer (CRC) limited to liver metastases (LM). After R0 resection of LM the high recurrence rate remains a major challenge. L-BLP25 is an antigen-specific cancer vaccine targeting mucin 1 (MUC1). The LICC trial aimed to improve survival outcome in mCRC patients (pts) after R0/R1 LM resection. Methods: This LICC trial, a binational, multicenter, double-blinded, placebo controlled phase II trial, included pts with stage IV LM limited CRC after resection of primary tumor and LM (R0/R1) within the last 8 weeks, ECOG 0/1 and adequate organ function. Pts were 2:1 randomized to receive L…

Cancer Researchmedicine.medical_specialtyColorectal cancerDouble blindedbusiness.industrymedicine.medical_treatmentImmunotherapyPlacebomedicine.diseaseGastroenterologyOncologyInternal medicinemedicineTecemotideMetastasectomybusinessAdjuvantR0 resectionJournal of Clinical Oncology
researchProduct

Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials ( LICC , CEL…

2021

Metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) have a chance of long-term survival and potential cure after hepatic metastasectomy. However, the appropriate postoperative treatment strategy is still controversial. The CELIM and FIRE-3 studies demonstrated that secondary hepatic resection significantly improved overall survival. The objective of this analysis was to compare these favorable outcome data with recent results from the LICC trial investigating the antigen-specific cancer vaccine tecemotide (L-BLP-25) as adjuvant therapy in mCRC patients with LLD after R0/R1 resection. Data from mCRC patients with LLD and secondary hepatic resection from each study w…

Cancer Researchmedicine.medical_specialtyColorectal cancerbusiness.industryDiseasemedicine.diseaseResectionSurgeryOncologyCohortmedicineAdjuvant therapyTecemotideCancer vaccineMetastasectomybusinessInternational Journal of Cancer
researchProduct

Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection

2021

Background: Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis. Methods: 124 HCC patients, who underwent a primary hepatic …

Cancer Researchmedicine.medical_specialtyHepatitis C virusSubgroup analysisLower riskmedicine.disease_causelcsh:RC254-282GastroenterologyArticlePathogenesisLoss of heterozygositynext-generation sequencing.03 medical and health sciences0302 clinical medicineInternal medicineMedicinePTENHCCHCC recurrencebiologybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinomaliver resectionbiology.proteinnext-generation sequencingloss of heterozygosity030211 gastroenterology & hepatologyLiver functionbusinessCancers
researchProduct

Incidence and patterns of late recurrences in colon cancer patients

2015

Long-term recurrences of colon cancer raised questions about the possible benefit of prolonging the recommended active 5-year surveillance. The aim of this study was to determine, for the first time, the incidence and patterns of late 10-year recurrence following curative resection of colon cancer. Data were obtained from two French digestive cancer registries. A total of 3,622 patients under 85 years resected for cure for colon cancer diagnosed between 1985 and 2000 were included. Information regarding recurrences was actively collected. Cumulative failure rates at 10 years were estimated using Kaplan-Meier estimates corrected by cause-specific hazards, and multivariable analysis was perfo…

Cancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerbusiness.industryIncidence (epidemiology)Female sexLower riskCompeting risksmedicine.diseaseSurgeryCancer registryOncologyColon cancer resectionmedicinebusinessInternational Journal of Cancer
researchProduct

Identification of High-Risk Atypical Meningiomas According to Semantic and Radiomic Features

2020

Up to 60% of atypical meningiomas (World Health Organization (WHO) grade II) reoccur within 5 years after resection. However, no clear radiological criteria exist to identify tumors with higher risk of relapse. In this study, we aimed to assess the association of certain radiomic and semantic features of atypical meningiomas in MRI with tumor recurrence. We identified patients operated on primary atypical meningiomas in our department from 2007 to 2017. An analysis of 13 quantitatively defined radiomic and 11 qualitatively defined semantic criteria was performed based on preoperative MRI scans. Imaging characteristics were assessed along with clinical and survival data. The analysis include…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTumor resectionlcsh:RC254-282survivalArticleWorld healthResection03 medical and health sciences0302 clinical medicineatypical meningiomamedicineUnivariate analysisbusiness.industryHazard ratiopredictionOdds ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalOncologyradiomics030220 oncology & carcinogenesisRadiologybusiness030217 neurology & neurosurgeryCancers
researchProduct

Przegląd metod śródoperacyjnej oceny marginesów w chirurgicznym leczeniu oszczędzającym gruczoł piersiowy

2021

Breast conserving therapy is the primary treatment modality in early-stage breast cancer patients. Despite the development of methods for the intraoperative assessment of tumor margins, 20–30% of patients still require re-resection due to postoperative tumor infiltration at the surgery margins. In recent years, many methods have been developed to reduce the number of re-resections due to margin infiltration. Here we review the current methods together with several more techniques under investigation.

Cancer Researchmedicine.medical_specialtySurgical marginbusiness.industrymedicine.medical_treatmentmedicine.diseaseRe resectionBreast cancerOncologyMargin (machine learning)medicineBreast-conserving surgeryPrimary treatmentRadiologybusinessNowotwory. Journal of Oncology
researchProduct

Extent of resection and survival in glioblastoma multiforme

2016

Brown and colleagues1 reported the results of a systematic review of the literature aimed in determining whether greater extent of resection (EOR) is associated with improved 1- and 2-year overall survival and 6-month and 1-year progression-free survival in patients affected by glioblastoma multiforme. The analysis revealed 37 studies suitable for inclusion. The authors found that gross total resection (GTR) for glioblastoma multiforme reduces 1- and 2-year mortality, thus supporting GTR over subtotal resection and biopsy.

Cancer Researchmedicine.medical_specialtybusiness.industryExtent of resectionmedicine.diseaseGross Total Resection03 medical and health sciences0302 clinical medicineOncologyextent of resection glioma gross total resection030220 oncology & carcinogenesisGliomaMedicineRadiologybusiness030217 neurology & neurosurgeryGlioblastoma
researchProduct

Intravesical mitoxantrone in superficial bladder tumours (Ta-T1)

1993

Abstract 36 patients with histologically proven grade G1–G2, Ta-T1 transitional cell carcinoma of the bladder were introduced, after transurethral resection (TUR), into a study of intravesical chemoprophylaxis with mitoxantrone (20 mg diluted in 50 ml). After a mean follow-up of 23 months, 16 (50%) patients showed a superficial recurrence with a mean recurrence rate of 0.56 per year. In 19 patients with recurring tumours the mean recurrence rate decreased from 1.65 to 0.58 per year. 9 patients (25.7%) suffered from a chemical cystitis that in 2 cases (5.7%) required treatment interruption.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyResectionCystitismedicineHumansCarcinoma Transitional CellMitoxantroneChemotherapyUrinary bladderbusiness.industrymedicine.diseaseSurgeryChemical cystitisAdministration IntravesicalTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyTreatment interruptionChemoprophylaxisMitoxantroneNeoplasm Recurrence Localbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

Laparoscopic Total Mesometrial Resection (L-TMMR)

2017

Abdominal radical hysterectomy and pelvic lymph node dis- section as introduced by Wertheim and Meigs [1–2] first in the beginning of the century is still regarded as “gold stan- dard” in the surgical treatment of the uterine cervix carci- noma, FIGO stages IA2-IB and IIA. The resection of the parametrial and paracervical tissues proposed by the conventional radical hysterectomy is based on a “centrifu- gal diffusion” from the center of the tumor on the direction of the parametrial (dorsal, lateral and ventral) highways. This imply a classic functional and ligament-focused view of the surgical anatomy.

Cervical cancermedicine.medical_specialtySurgical approachRadical Hysterectomybusiness.industryTumor resectionCervical Cancermedicine.diseaseSurgeryFertility sparing surgeryResectionSurgical anatomymedicineRadical HysterectomybusinessTMMR
researchProduct